GEHC · NMS · Healthcare
GE HealthCare Technologies Inc.
Also onShortfallConsensus DriftCrosscheck
Implied value per share
USD 72.60
Market price
USD 64.13
Implied upside
+13.2%
5-year forecast · Perpetuity growth terminal value · Mid-year discounting · Base case
Value Per Share
Same forecast, different terminal treatment. Percentages vs price.
Forecast Cashflows
Reporting currency (USD). Outflows negative.
| Line | FY26 | FY27 | FY28 | FY29 | FY30 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | USD 21.4bn | USD 22.3bn | USD 23.2bn | USD 24.1bn | USD 25.1bn | +4.0% |
| EBIT | USD 2.8bn | USD 3.0bn | USD 3.1bn | USD 3.2bn | USD 3.3bn | +4.0% |
| NOPAT | USD 2.2bn | USD 2.3bn | USD 2.4bn | USD 2.5bn | USD 2.6bn | +4.0% |
| Add depreciation & amortisation | USD 660.7m | USD 687.1m | USD 714.5m | USD 743.0m | USD 772.6m | +4.0% |
| Less capital expenditure | USD -431.4m | USD -448.6m | USD -466.5m | USD -485.1m | USD -504.4m | +4.0% |
| Less increase in working capital | USD -132.1m | USD -137.4m | USD -142.9m | USD -148.6m | USD -154.5m | +4.0% |
| Free cashflow to firm | USD 2.3bn | USD 2.4bn | USD 2.5bn | USD 2.6bn | USD 2.7bn | +4.0% |
| Discount factor | 0.9610 | 0.8876 | 0.8197 | 0.7571 | 0.6992 | - |
| Present value | USD 2.2bn | USD 2.2bn | USD 2.1bn | USD 2.0bn | USD 1.9bn | -4.0% |
| Present Value Of The Forecast | USD 10.4bn | |||||
Discount Rate
Source shown per component. All overridable above.
| Risk-free rate | 5.00% | US 10-year Treasury (^TNX) |
| Equity risk premium | 5.50% | Market assumption |
| Beta | 0.880 | Reported 0.821, pulled toward 1.0 (Blume) |
| Cost of equity | 9.84% | Risk-free + beta x equity risk premium |
| Cost of debt | 5.00% | Floored at the risk-free rate (implied cost of debt was lower) |
| Market capitalisation | USD 29.0bn | 73.5% of capital |
| Total debt | USD 10.5bn | 26.5% of capital, book value as a proxy |
| Tax rate | 21.0% | Effective, capped at statutory |
| WACC | 8.28% | E/V x Re + D/V x Rd x (1 - t) |
Terminal Value
Perpetuity growth is intrinsic. The exit multiple defaults to the company's current EV/EBITDA, so it answers a different question - what the shares are worth if today's rating holds and EBITDA grows as forecast.
Perpetuity growth at 2.50%
74% of EV
- Forecast FCFF, final year
- USD 2.7bn
- Capex at depreciation, working capital in reinvestment
- USD 3.0bn
- Less reinvestment at g/ROIC (21.8% of NOPAT)
- USD -648.3m
- Capitalised
- USD 2.3bn
- ROIC (reported)
- 11.5%
- Terminal value, undiscounted
- USD 41.2bn
- Terminal value, discounted
- USD 28.8bn
- Enterprise value
- USD 39.2bn
- Less net debt
- USD 6.0bn
- Equity value
- USD 33.3bn
Exit at 10.5x EBITDA
74% of EV
- Terminal value, undiscounted
- USD 42.8bn
- Terminal value, discounted
- USD 29.9bn
- Enterprise value
- USD 40.3bn
- Less net debt
- USD 6.0bn
- Equity value
- USD 34.3bn
Spread between methods: 3%.
Sensitivity
Value per share (USD) by discount rate and long-run growth.
| Long-run growth | |||||
|---|---|---|---|---|---|
| Discount rate | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
| 6.28% | 101.85 | 107.87 | 115.44 | 125.25 | 138.51 |
| 7.28% | 82.42 | 85.67 | 89.55 | 94.30 | 100.24 |
| 8.28% | 68.72 | 70.52 | 72.60 | 75.04 | 77.95 |
| 9.28% | 58.54 | 59.53 | 60.64 | 61.90 | 63.34 |
| 10.28% | 50.67 | 51.18 | 51.74 | 52.34 | 53.00 |
Outlined: this model. Green text: above today's price of 64.13. Shading: distance from this model's own value.
Priced In
What each input would have to be to justify the current price, one at a time.
| Input | Model | Implied | Gap |
|---|---|---|---|
| Revenue growth, every year | 4.0% | 1.3% | -2.6pp |
| EBIT margin | 13.2% | 11.8% | -1.5pp |
| Discount rate | 8.3% | 8.9% | +0.7pp |
Live formulas, not pasted numbers - edit a driver and the workbook reprices.
Yahoo Finance and RBA data. General information, not advice. Methodology.